Aptevo Therapeutics Inc. Earnings Per Share (Basic)
Aptevo Therapeutics Inc. (APVO) reported Earnings Per Share (Basic) of -$5.31 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- Aptevo Therapeutics Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$5.31.
- Aptevo Therapeutics Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$6.41.
- Aptevo Therapeutics Inc. earnings per share, basic for the quarter ending 2025-12-31 was $1.33, a 99.76% decline year-over-year.
- Aptevo Therapeutics Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$2.23.
- Aptevo Therapeutics Inc. earnings per share, basic for fiscal 2025 was -$87.27.
- Aptevo Therapeutics Inc. earnings per share, basic for fiscal 2024 was -$31460.23.
- Aptevo Therapeutics Inc. earnings per share, basic for fiscal 2023 was -$2316.83, a 147668.79% decline from fiscal 2022.
- Aptevo Therapeutics Inc. earnings per share, basic for fiscal 2022 was $1.57.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.31 10-Q · filed 2026-08-14 | -$11.19 10-Q · filed 2026-08-14 | $26.37 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$59.68 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2026-03-31 | -$6.41 10-Q · filed 2026-05-13 | $7.55 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$95.07 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$153.77 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-12-31 | $1.33 derived: net income ÷ weighted average shares · filed 2026-03-26 | $79.54 derived: net income ÷ weighted average shares · filed 2026-03-26 | $189.63 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$87.27 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | -$2.23 10-Q · filed 2025-11-06 | -$7.45 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$11.42 10-Q · filed 2025-11-06 | -$27.39 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-06-30 | -$151.29 10-Q · filed 2026-08-14 | -$8.40 10-Q · filed 2025-08-11 | -$555.08 10-Q · filed 2026-08-14 | -$30.84 10-Q · filed 2025-08-11 | -$1683.73 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$2003.25 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||
| 2025-03-31 | -$1581.81 10-Q · filed 2026-05-13 | -$4.39 10-Q · filed 2025-05-15 | $3489.71 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$7677.05 derived: net income ÷ weighted average shares · filed 2026-05-13 | ||||
| 2024-12-31 | $556.56 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$7835.91 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$31460.23 10-K · filed 2026-03-26 | -$87.38 10-K · filed 2025-02-14 | ||||
| 2024-09-30 | -$357.86 10-Q · filed 2025-11-06 | -$0.48 10-Q · filed 2024-11-07 | -$3709.76 10-Q · filed 2025-11-06 | -$5.01 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | -$1236.96 10-Q · filed 2025-08-11 | -$1.67 10-Q · filed 2024-08-08 | -$4458.98 10-Q · filed 2025-08-11 | -$6.02 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | -$368.21 10-Q · filed 2025-05-15 | -$9.95 10-Q · filed 2024-05-08 | ||||||
| 2023-12-31 | -$2316.83 10-K · filed 2025-02-14 | -$1.42 10-K · filed 2024-03-05 | ||||||
| 2023-09-30 | -$22.16 10-Q · filed 2024-11-07 | -$0.50 10-Q · filed 2023-11-14 | -$56.22 10-Q · filed 2024-11-07 | -$1.28 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | -$53.95 10-Q · filed 2024-08-08 | -$1.23 10-Q · filed 2023-08-10 | -$31.67 10-Q · filed 2024-08-08 | -$0.72 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $17.38 10-Q · filed 2024-05-08 | $0.39 10-Q · filed 2023-05-11 | ||||||
| 2022-12-31 | $1.57 10-K · filed 2024-03-05 | |||||||
| 2022-09-30 | -$1.50 10-Q · filed 2023-11-14 | $2.52 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | $5.58 10-Q · filed 2023-08-10 | $4.08 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | -$1.55 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | -$6.07 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | -$1.43 10-Q · filed 2022-11-10 | -$4.80 10-Q · filed 2022-11-10 | ||||||
| 2021-06-30 | -$1.75 10-Q · filed 2022-08-11 | -$3.39 10-Q · filed 2022-08-11 | ||||||
| 2019-09-30 | -$0.16 10-Q · filed 2019-11-07 | -$0.82 10-Q · filed 2019-11-07 | ||||||
| 2018-09-30 | -$0.55 10-Q · filed 2019-11-07 | -$0.56 10-Q · filed 2018-11-14 | -$1.76 10-Q · filed 2019-11-07 | -$1.77 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | -$0.58 10-Q · filed 2018-08-09 | -$1.21 10-Q · filed 2018-08-09 | ||||||
| 2018-03-31 | -$0.63 10-Q · filed 2018-05-10 | |||||||
| 2017-09-30 | $1.77 10-Q · filed 2018-11-14 | $0.79 10-Q · filed 2018-11-14 | ||||||
| 2017-06-30 | -$0.53 10-Q · filed 2018-08-09 | -$1.01 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | -$0.48 10-Q · filed 2018-05-10 | |||||||
| 2016-09-30 | -$3.55 10-Q · filed 2017-11-13 | -$4.82 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |